【官宣！全球生物制药巨头诺和诺德牵手互联网慢病管理巨头方舟健客(06086.HK) 以AI重构控糖减重管理价值链 共筑全球数智化新标杆】智通财经APP获悉，在“健康中国2030”战略深入实施与“体重管理年”政策大力推进的背景下，7月18日，“AI+互联网医疗”头部企业方舟健客(06086.HK)与全球领先的生物制药公司诺和诺德正式签署战略合作备忘录。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.